TY  - JOUR
AU  - Muñoz Builes, Mario
AU  - Vela Cuenca, María
AU  - Fuster Soler, Jose L
AU  - Astigarraga, Itziar
AU  - Pascual Martínez, Antonia
AU  - Vagace Valero, Jose M
AU  - Tong, Hoi Y
AU  - Valentín Quiroga, Jaime
AU  - Fernández Casanova, Lucía
AU  - Escudero López, Adela
AU  - Sisinni, Luisa
AU  - Blanquer, Miguel
AU  - Mirones Aguilar, Isabel
AU  - González Martínez, Berta
AU  - Borobia, Alberto M
AU  - Pérez-Martínez, Antonio
PY  - 2020
DO  - 10.1136/bmjopen-2019-029642
UR  - http://hdl.handle.net/10668/14938
T2  - BMJ open
AB  - Acute myeloblastic leukaemia (AML) constitutes the second most common haematological malignancy in the paediatric population. Current treatment regimens are based on the administration of polychemotherapy, combining high doses of cytarabine with...
LA  - en
KW  - immunology
KW  - leukaemia
KW  - paediatric oncology
KW  - Adolescent
KW  - Adult
KW  - Child
KW  - Child, Preschool
KW  - Consolidation Chemotherapy
KW  - Disease-Free Survival
KW  - Female
KW  - Follow-Up Studies
KW  - Hematopoietic Stem Cell Transplantation
KW  - Humans
KW  - Infant
KW  - Infant, Newborn
KW  - Killer Cells, Natural
KW  - Leukemia, Myeloid, Acute
KW  - Male
KW  - Prospective Studies
KW  - Transplantation, Homologous
KW  - Young Adult
TI  - Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia.
TY  - research article
VL  - 10
ER  -